- Sector: Healthcare
- Region: London
Making diagnostic-led care simpler and more accessible, LumiraDx was founded in 2014 by a group of entrepreneurs with more than three decades of experience. The LumiraDx Platform is designed to deliver lab-comparable diagnostic results at the point of care, within a few minutes. This includes fast and accurate COVID-19 tests. The Platform consists of a small, portable instrument, a microfluidic test strip and seamless, secure digital connectivity to the cloud and hospital IT systems.
Ron Zwanziger, Chair and Chief Executive Officer of LumiraDx, says that the COVID-19 pandemic has been challenging, but has also provided opportunities for the company. “In response to the COVID-19 pandemic and the resulting acute need for timely diagnostic information, LumiraDx developed SARS-CoV-2 antigen and SARS-CoV-2 antibody tests for use in community-based healthcare settings,” he says. LumiraDx is also working on providing access to Flu A/B-SARS-CoV-2 tests on the same test strip and Platform for the upcoming flu season.
Throughout the pandemic, LumiraDx was identified as a company delivering essential work and, while it moved as much of its workforce as possible to remote working, critical parts of its research and development, laboratory, manufacturing, engineering, quality and support teams continued to work on site in Stirling, Scotland.
Ron says the Healthcare sector is seeing trends towards more community-based healthcare settings and a need for near-patient testing, but the promise of better outcomes and lower costs has not been fully recognised yet. “We believe that to achieve better health outcomes, healthcare providers require comprehensive diagnostic solutions that can provide fast, accurate test results at the point of care for a broad range of their testing needs, all at a reasonable cost,” he explains. The LumiraDx Platform, he hopes, will transform the delivery of healthcare in community-based settings.